LL-37: Dosage, Protocol, and Research Guide
Antimicrobial peptide with immune-modulating and wound healing properties
Mechanism
Human cathelicidin that provides broad-spectrum antimicrobial activity, modulates immune responses, promotes angiogenesis, and accelerates epithelial wound healing.
Protocol at a glance
| Starting dose | 100mcg |
|---|---|
| Maintenance dose | 100-500mcg |
| Maximum dose | 500mcg |
| Frequency | Daily |
| Typical duration | 2-4 weeks |
| Route | Subcutaneous |
| Injection site | Near wound or infection site |
| Timing | Any time of day |
Side effects
- Injection site reactions
- Possible inflammatory response
Contraindications
- Autoimmune conditions
- Pregnancy
Protocol notes
- Natural antimicrobial peptide
- Fights bacteria, viruses, and fungi
- Promotes wound healing
- Modulates inflammatory response
- May help with chronic infections
Frequently asked questions
What is the recommended dosing protocol?
LL-37 is typically dosed at 100 micrograms initially, with maintenance doses ranging from 100 to 500 micrograms daily. The maximum recommended dose is 500 micrograms per day. Treatment protocols generally span 2 to 4 weeks. Administration is via subcutaneous injection, with injection sites positioned near the wound or infection site being treated. LL-37 can be administered at any time of day. These dosing parameters should only be followed under medical supervision.
How does this peptide work in the body?
LL-37 is a human-derived cathelicidin peptide that operates through multiple biological mechanisms. It provides broad-spectrum antimicrobial activity against bacteria, viruses, and fungi. Beyond direct antimicrobial effects, LL-37 modulates immune responses by activating immune cells and enhancing innate defenses. It also promotes angiogenesis—the formation of new blood vessels—which is crucial for delivering oxygen to healing tissue. LL-37 accelerates epithelial wound healing by stimulating cellular proliferation and repair. Additionally, it may help modulate inflammatory responses, calibrating immune activation to support healing rather than suppressing immunity.
Is this treatment legal and FDA-approved?
LL-37 is not FDA-approved for human use. It is currently available only for research purposes and within clinical trial settings. Any use should occur only under the supervision of a licensed physician in an appropriate research or clinical context. Before considering LL-37, individuals must consult with a healthcare provider, as its legal status and availability vary by jurisdiction.
What side effects should I expect?
The most common side effect is injection site reactions, which are typical of subcutaneous peptide administration. Some users may experience a possible inflammatory response as the immune system activates. These side effects are generally mild and self-limiting. LL-37 is contraindicated in individuals with autoimmune conditions, where immune activation could exacerbate existing disease, and in pregnancy, where its effects on fetal development remain unstudied.
Can this peptide be cycled or stacked with other treatments?
Research on LL-37 cycling and stacking protocols remains limited. The standard treatment duration is 2 to 4 weeks. Any consideration of cycling—stopping and restarting—or combining LL-37 with other treatments should only be undertaken under medical supervision. A physician experienced in peptide protocols should design any approach involving combination therapy, as research data on stacking remains sparse.
How can I assess if treatment is working?
Research on specific laboratory markers to assess LL-37 effectiveness remains limited. Clinical assessment typically focuses on the intended outcome: wound healing progression, infection resolution, or changes in immune markers. A physician overseeing treatment can order appropriate lab work based on the individual's specific health situation and treatment goals. Response varies between individuals.
Who shouldn't use this treatment?
LL-37 has specific contraindications that must be observed. It is contraindicated in individuals with autoimmune conditions, where the peptide's immune-modulating effects could worsen existing disease. LL-37 is also contraindicated in pregnancy, as its effects on fetal development have not been adequately studied. These contraindications should be carefully reviewed with a healthcare provider before considering use.
More Healing & Recovery peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.